| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ARTICLES |
Division of Endocrinology, Metabolism, and Diabetes (D.F.G., W.W.W., S.R.L., W.M.W., E.C.R.), University of Colorado Health Sciences Center, Denver, Colorado; and Department of Medicine (R.A.J.), University of Newcastle, Newcastle-upon-Tyne, United Kingdom
Address all correspondence and requests for reprints to: Dr. David F. Gordon, University of Colorado Health Sciences Center, Division of Endocrinology, Box B151, 4200 East Ninth Avenue, Denver, Colorado 80262. E-mail: david.gordon{at}uchsc.edu
Somatostatin is a peptide hormone whose actions are mediated by five somatostatin receptor subtypes (sst15). In the pituitary, somatostatin inhibits TSH release from thyrotropes and GH release from somatotropes. We have shown that sst5 transcripts and protein are induced by thyroid hormone in TtT-97 thyrotropic tumors. To map sequences responsible for promoter activity in pituitary cells, we cloned the mouse sst5 coding region of 362 amino acids and 12 kb of upstream DNA. Initial transfection studies in TtT-97 or GH3 cells mapped high levels of basal promoter activity to a 5.6-kb fragment upstream of the translational start, whereas shorter genomic fragments had low activity. To identify the transcriptional start site we used 5' RACE with TtT-97 poly A+ RNA and a sst5 antisense coding region primer. Sequence comparison between the complementary DNA and the gene revealed that the mouse sst5 gene contains 3 exons and 2 introns. The entire coding region was contained in exon 3. Two differently sized RACE products demonstrated alternate exon splicing of two untranslated exons in TtT-97 cells. A promoter fragment from -290/+48 linked to a luciferase reporter demonstrated 600- and 900-fold higher activity over a promoterless control in GH3 mammosomatotropes and TtT-97 thyrotropes, respectively, whereas a larger fragment extending to -6400 exhibited no additional promoter activity. Cloning of the sst5 gene will facilitate the mapping of basal and regulated responses at the transcriptional level.
This article has been cited by other articles:
![]() |
C de Bruin, R A Feelders, A M Waaijers, P M van Koetsveld, D M Sprij-Mooij, S W J Lamberts, and L J Hofland Differential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitro J. Mol. Endocrinol., January 1, 2009; 42(1): 47 - 56. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. van der Hoek, M. Waaijers, P. M. van Koetsveld, D. Sprij-Mooij, R. A. Feelders, H. A. Schmid, P. Schoeffter, D. Hoyer, D. Cervia, J. E. Taylor, et al. Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E278 - E287. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Petersenn, A. C. Rasch, C. Bohnke, and H. M. Schulte Identification of an Upstream Pituitary-Active Promoter of Human Somatostatin Receptor Subtype 5 Endocrinology, July 1, 2002; 143(7): 2626 - 2634. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. W. Woodmansee, R. L. Mouser, D. F. Gordon, J. M. Dowding, W. M. Wood, and E. C. Ridgway Mutational Analysis of the Mouse Somatostatin Receptor Type 5 Gene Promoter Endocrinology, June 1, 2002; 143(6): 2268 - 2276. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |